Mirum Pharmaceuticals Turns to Q3 Net Loss of $40.77 Million

• Mirum Pharmaceuticals swung to a third-quarter 2026 net loss of $40.77 million from net income of $2.91 million a year earlier.
• Net product sales climbed 40% year over year to $185.72 million, while operating expenses rose 88% to $245.47 million.
• ATEBRIOZ received U.S. FDA approval for fibrodysplasia ossificans progressiva in patients aged 12 and older, and launched.
• Phase 3 studies of LIVMARLI in additional rare cholestatic conditions and brelovitug in chronic hepatitis delta virus met their primary endpoints.
• Full-year 2026 net product sales guidance increased to $715 million–$720 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611031601BIZWIRE_USPR_____20261103_BW832135) on November 03, 2026, and is solely responsible for the information contained therein.